16 September 2026 note archive · Item
Insulin glargine U300 (Toujeo): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin glargine U300 (Toujeo)
Scope and findings:
- Read DailyMed/EMA: U300 not interchangeable withU100;steady state>=5days,onset develops over6h,unit-for-unit glucose effect lower;adult/pediatric use. Comparative benefits and regional prices not newly reverified.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.